On the afternoon of April 12, 2021, a bilateral meeting between the China National Medical Products Administration (NMPA) and the Japan Pharmaceuticals and Medical Devices Agency (PMDA) was held online for in-depth exchanges on the bilateral cooperation in drug supervision between China and Japan. Chen Shifei, Deputy Commissioner of the China NMPA, Yasuhiro Fujiwara, Chief Executive of the Japan PMDA, and relevant officials of the Japan Ministry of Health, Labor and Welfare of Japan (MHLW) attended the meeting.
Deputy Commissioner Chen said that leaders of China and Japan have reached important consensus on building China-Japanese relations that meet the requirements of the new era in recent years. The mutual support and cooperation between drug regulatory authorities of China and Japan in bilateral and multilateral areas such as ICH, is conducive to not only the common development of the two countries, but also the health of people.
Yasuhiro Fujiwara, Chief Executive of PMDA, said that China and Japan have more new opportunities for bilateral cooperation since the outbreak of COVID-19, and PMDA hopes to further strengthen amicable relations with Chinese drug regulatory authorities, continue to deepen the cooperation, and enhance the exchanges and cooperation of both parties in international organizations such as ICH, and further boost the coordination of global rules in the field of drug regulation.
At the meeting, both parties had an in-depth exchange of views on visits, information exchange and regulatory cooperation. The two parties agreed to further strengthen exchanges and cooperation to help the global fight against the pandemic and safeguard public health.